Zetagen
Syracuse, US · Founded 2015 · 1 known investors
Zetagen develops molecular therapies, including its ZetaMet (Zeta-BC-003) drug, that aim to suspend cancer, inhibit pain, and regenerate bone in patients with metastatic and primary bone cancers. The locally administered treatments are adjunctive to other cancer therapies and target patients living with bone metastases, primarily in the United States.
Founders & leadership
Zetagen was founded in 2015 by Joe C Loy.
JC
Joe C LoyFounder
PB
Peter B. FinnExecutive
NT
Nikhil Thakur, MDExecutive
DT
David TischlerExecutive
Board
RW
Richard WarburgBoard director
AK
Ashok KaveeshwarBoard director
DB
Donald BrownBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$26.1M disclosed across 5 rounds · 2017–2025
▶$12.9MraisedNov 2025 · 35 investors · PharmaceuticalsRule 506(b)
▶$12.9MraisedNov 2025 · 35 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joe C LoyExecutive Officer, Director
- Richard WarburgDirector
- Ashok KaveeshwarDirector
- Peter B. FinnExecutive Officer
- Nikhil Thakur, MDExecutive Officer, Director
- Donald BrownDirector
- Offering amount
- $13M
- Amount sold
- $12.9M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.6MraisedFeb 2023 · 44 investors · PharmaceuticalsRule 506(b)
▶$9.6MraisedFeb 2023 · 44 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter B. FinnExecutive Officer
- Joe C LoyDirector
- Donald BrownDirector
- Richard WarburgDirector
- Ashok KaveeshwarDirector
- Nikhil Thakur, MDExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $9.6M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$840KraisedDec 2019 · 4 investors · PharmaceuticalsRule 506(b)
▶$840KraisedDec 2019 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nikhil Thakur, MDExecutive Officer, Director
- Joe C LoyExecutive Officer, Director
- Peter B. FinnExecutive Officer
- Offering amount
- $8.5M
- Amount sold
- $840K
- Minimum investment
- $5K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1MraisedDec 2018 · 30 investors · PharmaceuticalsRule 506(b)
▶$1MraisedDec 2018 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David TischlerExecutive Officer, Director
- Peter B. FinnExecutive Officer, Director
- Nikhil Thakur, MDExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $5K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.7MraisedFeb 2018 · 47 investors · BiotechnologyRule 506(b)
▶$1.7MraisedFeb 2018 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter B. FinnExecutive Officer, Director
- Nikhil Thakur, MDExecutive Officer, Director
- David TischlerExecutive Officer, Director
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Minimum investment
- $10K
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $301.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Zetagen do?
- Zetagen develops molecular therapies, including its ZetaMet (Zeta-BC-003) drug, that aim to suspend cancer, inhibit pain, and regenerate bone in patients with metastatic and primary bone cancers. The locally administered treatments are adjunctive to other cancer therapies and target patients living with bone metastases, primarily in the United States.
- Who founded Zetagen?
- Zetagen was founded by Joe C Loy in 2015.
- Who are Zetagen's investors?
- Zetagen's investors include JStar Capital Investments.
- How much funding has Zetagen raised?
- Zetagen has disclosed $26.1M raised across 5 rounds.
- Where is Zetagen headquartered?
- Zetagen is headquartered in Syracuse, US.